Gilead Sciences, Inc. (NASDAQ:GILD) Position Boosted by Brighton Jones LLC

Brighton Jones LLC boosted its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 4.8% in the 1st quarter, Holdings Channel reports. The institutional investor owned 15,050 shares of the biopharmaceutical company’s stock after buying an additional 691 shares during the period. Brighton Jones LLC’s holdings in Gilead Sciences were worth $1,686,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. Annis Gardner Whiting Capital Advisors LLC lifted its stake in Gilead Sciences by 158.8% during the fourth quarter. Annis Gardner Whiting Capital Advisors LLC now owns 352 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 216 shares during the last quarter. Morton Brown Family Wealth LLC acquired a new position in shares of Gilead Sciences in the 4th quarter valued at about $35,000. Whipplewood Advisors LLC acquired a new position in shares of Gilead Sciences in the 4th quarter valued at about $35,000. Synergy Investment Management LLC bought a new stake in shares of Gilead Sciences during the 4th quarter valued at about $40,000. Finally, Lee Danner & Bass Inc. acquired a new stake in Gilead Sciences during the fourth quarter worth about $41,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Price Performance

Shares of NASDAQ:GILD opened at $109.98 on Monday. The stock’s 50 day moving average price is $105.67 and its 200 day moving average price is $102.33. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20. The stock has a market cap of $136.81 billion, a price-to-earnings ratio of 297.24, a PEG ratio of 0.71 and a beta of 0.29. Gilead Sciences, Inc. has a 12 month low of $62.69 and a 12 month high of $119.96.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share for the quarter, beating the consensus estimate of $1.77 by $0.04. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. The business had revenue of $6.67 billion during the quarter, compared to analyst estimates of $6.77 billion. During the same quarter in the prior year, the firm posted ($1.32) earnings per share. The company’s revenue was down .3% on a year-over-year basis. Equities research analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 27th. Stockholders of record on Friday, June 13th will be given a dividend of $0.79 per share. The ex-dividend date is Friday, June 13th. This represents a $3.16 annualized dividend and a dividend yield of 2.87%. Gilead Sciences’s dividend payout ratio (DPR) is 66.53%.

Analysts Set New Price Targets

A number of equities analysts have commented on the company. Cantor Fitzgerald initiated coverage on Gilead Sciences in a research note on Tuesday, April 22nd. They issued an “overweight” rating and a $125.00 target price for the company. Wells Fargo & Company upped their price objective on Gilead Sciences from $120.00 to $140.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 5th. Morgan Stanley increased their target price on Gilead Sciences from $130.00 to $135.00 and gave the stock an “overweight” rating in a research report on Friday, April 25th. Bank of America boosted their price target on shares of Gilead Sciences from $116.00 to $126.00 and gave the company a “buy” rating in a report on Wednesday, March 5th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Gilead Sciences in a report on Wednesday, May 21st. Nine analysts have rated the stock with a hold rating, fifteen have issued a buy rating and three have given a strong buy rating to the company’s stock. According to data from MarketBeat, Gilead Sciences presently has a consensus rating of “Moderate Buy” and a consensus target price of $110.55.

Insider Transactions at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 2,500 shares of the company’s stock in a transaction on Thursday, May 15th. The stock was sold at an average price of $99.82, for a total transaction of $249,550.00. Following the completion of the sale, the chief financial officer now directly owns 165,674 shares of the company’s stock, valued at $16,537,578.68. This represents a 1.49% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Daniel Patrick O’day sold 10,000 shares of the stock in a transaction on Friday, May 30th. The shares were sold at an average price of $110.42, for a total value of $1,104,200.00. Following the completion of the transaction, the chief executive officer now owns 620,268 shares of the company’s stock, valued at $68,489,992.56. This trade represents a 1.59% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 43,000 shares of company stock valued at $4,630,310 in the last quarter. Insiders own 0.27% of the company’s stock.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.